Overview
Pharmaceutical

Eisai Co.,Ltd.

Eisai is a Japan-based global research-driven pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription and over-the-counter medicines. The company's key therapeutic areas include neurology (notably Alzheimer's disease with its anti-amyloid antibody Leqembi/lecanemab) and oncology (including Lenvima/lenvatinib and tazemetostat). Operating under its 'human health care' (hhc) philosophy, Eisai also actively engages in access-to-medicine initiatives in developing countries, including the supply of lymphatic filariasis treatments across 33 nations.

Market Cap
¥1,434B
US$9.14B
EV
¥1,434B
US$9.14B
Stock¥5,076▲+0.42%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
16.4
x
LTM EV/EBIT
29.2
x
LTM PER
33.9
x
LTM PBR
1.6
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-8.7%pt
10012
Oct 24, 25 – Oct 23, 26StockTOPIX
1Nov 25, 25Novo Nordisk dementia drug trial failure boosts Leqembi competitive advantage hopes
2Jul 29, 26Lekembi Q1 (Apr-Jun) sales +27% YoY to ¥29.3bn (preliminary)
MC → EV Bridge
1,434BUS$9.14BMarket Cap314BUS$2.01B+ Debt312BUS$1.99B− Cash29.4BUS$187M− Inv. Sec.26.6BUS$170M+ NCI1,434BUS$9.14BEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
756US$4.82B'22/3744US$4.75B'23/3742US$4.73B'24/3789US$5.03B'25/3825US$5.26B'26/3
EBITDA 5Y (¥B)
92.1US$588M'22/380.0US$510M'23/392.8US$592M'24/394.3US$601M'25/383.7US$534M'26/3
Net Income 5Y (¥B)
48.0US$306M'22/355.4US$354M'23/342.4US$270M'24/346.4US$296M'25/338.6US$246M'26/3
Capital Structure
74%
26%
EquityD/E 0.35xDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
310US$1.97B95.6US$610M'22/3267US$1.71B127US$808M'23/3305US$1.94B160US$1.02B'24/3266US$1.69B231US$1.47B'25/3245US$1.57B229US$1.46B'26/3
Shareholders
Top 10 hold 45.4%
1
The Master Trust Bank of Japan, Ltd. (Trust Account)
18.55%
2
Custody Bank of Japan, Ltd. (Trust Account)
9.99%
3
STATE STREET BANK AND TRUST COMPANY 505001 (Standing Proxy: Mizuho Bank, Ltd.)
5.31%
4
JPMorgan Securities Japan Co., Ltd.
2.67%
5
Nippon Life Insurance Company (Standing Proxy: The Master Trust Bank of Japan, Ltd.)
2.30%
6
Goldman Sachs Japan Co., Ltd. BNYM (Standing Proxy: MUFG Bank, Ltd.)
1.83%
7
Naito Memorial Foundation for the Promotion of Science (Public Interest Foundation)
1.49%
8
JP MORGAN CHASE BANK 385781 (Standing Proxy: Mizuho Bank, Ltd.)
1.39%
9
STATE STREET BANK AND TRUST COMPANY 505103 (Standing Proxy: Mizuho Bank, Ltd.)
0.93%
10
HSBC HONG KONG-TREASURY SERVICES A/C ASIAN EQUITIES DERIVATIVES (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
0.93%
Management
12 officers
Haruo NAITO
Director
Oct 1975 Joined Eisai Co., Ltd. Apr 1983 General Manager, Research and Development Promotion Department Jun 1983 Director Apr 1985 General Manager, Research and Development Headquarters Jun 1985 Managing Director Jun 1986 Representative Director, Senior Managing Director Jun 1987 Representative Director, Executive Vice President Apr 1988 Representative Director, President Jun 2003 Representative Director, President and CEO Jun 2004 Director; Representative Executive Officer, President (CEO) Jan 2006 Chairman, Naito Memorial Foundation for the Promotion of Science (current) Jun 2014 Director; Representative Executive Officer, CEO (current)
1947-12-27
Fumihiko IKE
Director, Chairman of the Board
Feb 1982 Joined Honda Motor Co., Ltd. Jun 2003 Director, General Manager, General Purpose Products Division, Honda Motor Co., Ltd. Apr 2006 Director, General Manager, Business Administration Division, Honda Motor Co., Ltd. Jun 2007 Managing Director, General Manager, Business Administration Division, Honda Motor Co., Ltd. Apr 2008 Managing Director, General Manager, Asia and Oceania Division, Honda Motor Co., Ltd.; President and Director, Asia Honda Motor Company Limited (resigned Mar 2011) Apr 2011 Director, Senior Managing Executive Officer, General Manager, Business Administration Division, Honda Motor Co., Ltd.; Chief Risk Management Officer; in charge of Systems Apr 2012 Director, Senior Managing Executive Officer, General Manager, Business Administration Division and IT Division, Honda Motor Co., Ltd.; Chief Risk Management Officer; in charge of External Affairs Apr 2013 Representative Director, Chairman, Honda Motor Co., Ltd. (resigned Jun 2016) May 2014 Chairman, Japan Automobile Manufacturers Association (resigned May 2016) Jun 2020 Outside Director, NTT DATA Corporation (now NTT DATA Group Corporation) Jun 2021 Director, Eisai Co., Ltd. Jun 2021 Outside Director, Resona Holdings, Inc. (current) Jun 2023 Director, Chairman of the Board, Eisai Co., Ltd. (current)
1952-05-26
Hiroyuki KATO
Director
Apr 1982 Joined Eisai Co., Ltd. Jun 2010 Assistant to Chief Product Creation Officer; Senior Manager Jun 2011 Executive Officer (Riji) Apr 2012 Senior Manager, Product Creation Division Jun 2012 Executive Officer Jun 2012 General Manager, Portfolio Strategy and Promotion Department, Product Creation Division Apr 2016 Executive Officer Apr 2016 General Manager, Medicine Development Center Jun 2017 General Manager, Medicine Development Center; in charge of hhc Data Creation and Global Emergency Response Jan 2018 Chief Quality Officer; in charge of Global Emergency Response Jun 2019 Senior Executive Officer Jun 2019 Chief Clinical Quality Officer; Chief Product Quality Officer; in charge of Global Emergency Response and Regulatory Affairs Jun 2022 Director (current)
1957-09-08
Richard THORNLEY
Director
Sep 1983 Joined Westland Helicopters Ltd. Dec 1997 General Manager, Japan, AgustaWestland Jan 2003 Regional Director, North East Asia (Japan, Korea, Taiwan), AgustaWestland Jan 2004 President, Rolls-Royce Japan; President, Rolls-Royce Korea Jan 2014 Representative Director, President, Bell Helicopter Japan K.K. (resigned Mar 2018) Mar 2018 Chief Executive Officer, Thornley International (current) Jun 2019 Audit Committee Member, International Security Industry Association Jun 2022 Director, Eisai Co., Ltd. (current)
1964-11-25
Toru MORIYAMA
Director
Apr 1977 Joined Mitsubishi Corporation Apr 2001 Manager, Seafood Unit, Food Division, Mitsubishi Corporation Apr 2004 General Manager, Lifestyle Industries Department, Chubu Branch, Mitsubishi Corporation Sep 2005 Executive Officer, Lawson, Inc. May 2006 Director, Senior Managing Executive Officer, Lawson, Inc. Apr 2008 Executive Officer, Mitsubishi Corporation Apr 2009 Executive Officer, Assistant to CEO of Lifestyle Industries Group (in charge of Next-Generation Business Development), Mitsubishi Corporation Apr 2010 Managing Executive Officer, COO, Lifestyle Industries Group, Mitsubishi Corporation Apr 2011 Managing Executive Officer, CEO, Lifestyle Industries Group, Mitsubishi Corporation Jun 2011 Outside Director, Mitsubishi Shokuhin Co., Ltd. (resigned Mar 2013) Apr 2013 Managing Executive Officer, General Manager, Asia and Oceania, Mitsubishi Corporation Apr 2016 President and Executive Officer, Mitsubishi Shokuhin Co., Ltd. Jun 2016 Representative Director, President, Mitsubishi Shokuhin Co., Ltd. Jun 2021 Senior Advisor, Mitsubishi Shokuhin Co., Ltd. (resigned Jun 2022) Jun 2023 Director, Eisai Co., Ltd. (current)
1954-08-09
Yuiko YASUDA
Director
Apr 1985 Joined IBM Japan, Ltd. Sep 1991 Joined Booz Allen Hamilton Inc. Sep 1993 Joined Russell Reynolds Associates, Inc. Jun 1996 Managing Director, Russell Reynolds Associates, Inc. Apr 2003 Head of Japan Office and Executive Committee Member, Russell Reynolds Associates, Inc. Apr 2013 Executive Committee Member, Russell Reynolds Associates, Inc. Jun 2015 Outside Director, SCSK Corporation Jun 2016 Outside Director (Audit and Supervisory Committee Member), SCSK Corporation Mar 2017 Outside Director, Showa Shell Sekiyu K.K. (now Idemitsu Kosan Co., Ltd.) Jun 2018 Outside Director (Audit and Supervisory Committee Member), Murata Manufacturing Co., Ltd. Apr 2019 Outside Director, Idemitsu Kosan Co., Ltd. Jun 2020 Outside Director, Nippon Suisan Kaisha, Ltd. (now Nissui Corporation) Jun 2020 Outside Director (Audit and Supervisory Committee Member), Murata Manufacturing Co., Ltd. (current) Jul 2020 Senior Partner, Board Advisors Co., Ltd. (formerly Corporate Governance Promotion Organization) May 2023 Vice President and Director, Board Advisors Co., Ltd. (current) Jun 2023 Director, Eisai Co., Ltd. (current) Jun 2025 Outside Director, Kajima Corporation (current)
1961-09-16
Takuji KANAI
Director
Apr 1981 Joined Asahi & Co. (now Azsa LLC), Tokyo Office Mar 1984 Registered as Certified Public Accountant Sep 1985 Worked at New York Office of Asahi & Co. (until Aug 1990) Aug 1996 Member, Asahi & Co. Aug 2001 Representative Member, Asahi & Co. (now Partner) Jun 2008 Executive Director, Asahi & Co. Sep 2009 Chairman, Senior Review Committee, Asahi & Co. Jul 2011 Head of Fourth Business Division, Tokyo Office, Asahi & Co. Jul 2015 Senior Managing Director, Asahi & Co.; Head of Audit, KPMG Japan Apr 2016 Head of Audit, KPMG Asia Pacific (resigned Jun 2024) Jun 2019 Vice Chairman, Azsa LLC (resigned Jun 2021) Jun 2024 Director, Eisai Co., Ltd. (current) Jun 2024 Outside Director, The Gunma Bank, Ltd. (current)
1959-03-05
Kenta TAKAHASHI
Director
Apr 1983 Joined Eisai Co., Ltd. Jun 2001 General Manager, Legal Department Jun 2007 Executive Officer Jun 2007 General Counsel Jun 2009 In charge of Intellectual Property Jun 2011 Senior Executive Officer Apr 2016 Representative Director, President, Eisai R&D Management Co., Ltd. Jun 2019 Senior Executive Officer Jun 2021 In charge of Internal Audit Jun 2023 Chief Compliance Officer Jun 2023 In charge of Internal Control Jun 2024 Director (current)
1959-09-22
Yasushi OKADA
Director
Apr 1981 Joined Eisai Co., Ltd. Apr 2005 General Manager, Business Promotion Department, Pharmaceutical Business Division Jun 2005 Executive Officer Jan 2008 General Manager, Asia, Oceania and Middle East Business Division Aug 2008 President, Eisai Asia Regional Services Pte. Ltd. Apr 2009 In charge of Asia, Oceania and Middle East Business Jun 2010 Senior Executive Officer Jun 2010 General Manager, Financial Strategy Department, Finance and Accounting Division Jun 2011 Executive Officer Jun 2011 Chief Talent Officer Jun 2012 Senior Executive Officer Jun 2012 Chairman, Eisai Corporate Pension Fund Jun 2013 Executive Vice President Jun 2014 In charge of General Affairs, Environment, Health and Safety Jun 2017 Representative Executive Officer Jun 2017 In charge of Industry Affairs and China Business Jan 2018 In charge of Data Integrity Jun 2019 Representative Executive Officer, COO May 2021 Chairman, Japan Pharmaceutical Manufacturers Association May 2023 Chairman, Japan Pharmaceutical Federation Jun 2024 In charge of Internal Audit Jun 2025 Director (current)
1958-09-26
Ryoko UEDA
Director
Oct 2001 Joined Mizuho Securities Co., Ltd. Apr 2002 Japan Investment Environment Research Institute, Inc. (now Mizuho Investor Relations Co., Ltd.) Nov 2013 Special Researcher, Financial Research Center, Financial Services Agency Nov 2017 Director, Mizuho International plc (London) Nov 2019 Chief Researcher, Japan Investment Environment Research Institute, Inc. (now Mizuho Investor Relations Co., Ltd.) Feb 2020 Outside Director, Money Forward, Inc. Apr 2022 Member, Certified Public Accountants and Auditing Oversight Board (current) Jun 2022 Professor, SBI Graduate School (current) Jun 2022 Outside Director, Hirata Corporation (current) Oct 2022 Visiting Professor, Graduate School of Management, Kyoto University (current) Jun 2023 Outside Director, TOKAI Holdings Corporation (current) Jun 2024 Outside Director, Koei Chemical Co., Ltd. (current) Jun 2025 Director, Eisai Co., Ltd. (current)
1973-02-25
Koichi KAWANA
Director
Yuko TOYODA
Director
Large Shareholding Reports
BlackRock Japan Co., Ltd.
2026-07-21
1.92%→1.92%
Nomura Asset Management Co., Ltd.
2026-07-06
6.16%→7.29%
BlackRock Fund Advisors
2026-05-22
2.04%→2.11%
BlackRock Fund Advisors
2026-04-03
1.98%→2.04%
BlackRock Japan Co., Ltd.
2025-11-05
2.05%→1.98%
Sumitomo Mitsui Trust Asset Management Co., Ltd.
2025-09-19
2.67%→3.33%
BlackRock Japan Co., Ltd.
2025-09-18
2.06%→2.05%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-03
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-07-21
Large Shareholding Report
EDINET
2026-07-06
Large Shareholding Report
EDINET
2026-06-12
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-05-22
Large Shareholding Report
TDnet
2026-05-16
株主総会招集通知
EDINET
2026-04-03
Large Shareholding Report
TDnet
2026-02-09
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-12
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-11-05
Large Shareholding Report
EDINET
2025-09-19
Large Shareholding Report
EDINET
2025-09-18
Large Shareholding Report
TDnet
2025-08-05
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-13
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-07
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-08
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-02
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-14
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-07
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-09
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-21
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-09
Quarterly Securities Report
EDINET
2022-08-05
Quarterly Securities Report
EDINET
2022-06-17
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-09
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-06-18
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →